A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation

BACKGROUND: Currently, there are no effective medications to reverse periodontal disease (PD)-induced bone loss. The objective of this study was to test a new anabolic compound, LLP2A-Ale, or with the combination treatment of mesenchymal stromal cell (MSC), in the treatment of bone loss secondary to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Pharmacol Toxicol
Autors principals: Jiang, Min, Liu, Lixian, Liu, Ruiwu, Lam, Kit S., Lane, Nancy E., Yao, Wei
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7664094/
https://ncbi.nlm.nih.gov/pubmed/33187558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-020-00454-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars